Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325163 | 0.86 | CBFB (0.52) | HSD17B10CBFBMAOADYRK1ATDP1 | |
| SCHEMBL4976888 | 0.82 | KDM4E (0.31) | — | |
| SCHEMBL9305475 | 0.82 | KIF11 (0.39) | HSD17B10TYMS | |
| SCHEMBL11808209 | 0.81 | KIF11 (0.38) | HSD17B10TYMSRIPK1 | |
| SCHEMBL10707110 | 0.79 | CNR1 (0.37) | — | |
| SCHEMBL7977592 | 0.79 | KDM4E (0.38) | HSD17B10PARP1 | |
| SCHEMBL727387 | 0.79 | TYMS (0.49) | HSD17B10CBFBTYMSTDP1ILK | |
| SCHEMBL19364508 | 0.79 | HSD17B10 (0.40) | HSD17B10CBFBMAOADYRK1ATYMS | |
| SCHEMBL889001 | 0.79 | HSD17B10 (0.47) | HSD17B10CBFBMAOADYRK1ATDP1 | |
| SCHEMBL21708439 | 0.78 | MAOA (0.40) | CBFBMAOADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240230952-A1 | LAMINATE AND METHOD FOR MANUFACTURING LAMINATE | FUJIFILM CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240027897-A1 | LAMINATE AND MANUFACTURING METHOD OF LAMINATE | FUJIFILM CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230384671-A1 | LAMINATE OF NEGATIVE TONE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF PREPARING NEGATIVE TONE LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-9274422-B2 | Photosensitive resin composition, method for forming pattern-cured film using photosensitive resin composition, and electronic component | HITACHI CHEMICAL DUPONT MICROSYSTEMS, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20140120462-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING PATTERN-CURED FILM USING PHOTOSENSITIVE RESIN COMPOSITION, AND ELECTRONIC COMPONENT | HITACHI CHEMICAL DUPONT MICROSYSTEMS, LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| CN-1642941-A | 1-N-aminobenzimidazole derivatives | ZERIA PHARM CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-6838465-B2 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1167369-A1 | NOVEL THIAZOLOBENZIMIDAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| WO-2001034573-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | disclosed |
| CN-1271731-A | New thiazole benzimidazole derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2000-11-01 | — | — | CN | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0457331-B1 | Piperidine derivatives and antiulcer composition containing the same | MEIJI SEIKA KAISHA (JP) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| US-5185347-A | PIPERIDINE COMPOUNDS AND ANTIULCER COMPOSITION CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 1993-02-09 | — | — | US | disclosed |
| EP-0457331-A1 | Piperidine derivatives and antiulcer composition containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | CYP1B1, CYP2E1, CYP1A1 | HSD17B10 247/4885CBFB 755/4885MAOA 272/4885 |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | HSD17B10 954/4885CBFB 2862/4885MAOA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.